MX2012006696A - Derivados de 3, 4, 4a, 10b-tetrahidro-1h-tiopirano-[4, 3-c]-isoqunolina. - Google Patents
Derivados de 3, 4, 4a, 10b-tetrahidro-1h-tiopirano-[4, 3-c]-isoqunolina.Info
- Publication number
- MX2012006696A MX2012006696A MX2012006696A MX2012006696A MX2012006696A MX 2012006696 A MX2012006696 A MX 2012006696A MX 2012006696 A MX2012006696 A MX 2012006696A MX 2012006696 A MX2012006696 A MX 2012006696A MX 2012006696 A MX2012006696 A MX 2012006696A
- Authority
- MX
- Mexico
- Prior art keywords
- thiopyrano
- tetrahydro
- isoquinoline derivatives
- isoquinoline
- derivatives
- Prior art date
Links
- ZQCSTHXMOLTGJA-UHFFFAOYSA-N 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline Chemical class N1=CC2=CC=CC=C2C2C1CCSC2 ZQCSTHXMOLTGJA-UHFFFAOYSA-N 0.000 title 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09179982 | 2009-12-18 | ||
| US31555210P | 2010-03-19 | 2010-03-19 | |
| PCT/EP2010/069704 WO2011073231A1 (en) | 2009-12-18 | 2010-12-15 | 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4, 3-c] ISOQUINOLINE DERIVATIVES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012006696A true MX2012006696A (es) | 2012-07-17 |
Family
ID=41718903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012006696A MX2012006696A (es) | 2009-12-18 | 2010-12-15 | Derivados de 3, 4, 4a, 10b-tetrahidro-1h-tiopirano-[4, 3-c]-isoqunolina. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9018175B2 (enExample) |
| EP (2) | EP2513119B1 (enExample) |
| JP (1) | JP5645961B2 (enExample) |
| KR (1) | KR20120123313A (enExample) |
| CN (1) | CN102652136B (enExample) |
| AR (1) | AR079451A1 (enExample) |
| AU (1) | AU2010332955B8 (enExample) |
| BR (1) | BR112012014058A8 (enExample) |
| CA (1) | CA2784013A1 (enExample) |
| CO (1) | CO6551705A2 (enExample) |
| DK (1) | DK2513119T3 (enExample) |
| EA (1) | EA023212B1 (enExample) |
| ES (2) | ES2621291T3 (enExample) |
| GE (1) | GEP20146105B (enExample) |
| HR (1) | HRP20140893T1 (enExample) |
| ME (1) | ME01914B (enExample) |
| MX (1) | MX2012006696A (enExample) |
| NZ (1) | NZ601115A (enExample) |
| PH (1) | PH12012501125A1 (enExample) |
| PL (1) | PL2513119T3 (enExample) |
| PT (1) | PT2513119E (enExample) |
| RS (1) | RS53544B1 (enExample) |
| SG (2) | SG196785A1 (enExample) |
| SI (1) | SI2513119T1 (enExample) |
| SM (1) | SMT201400185B (enExample) |
| TW (1) | TWI468411B (enExample) |
| UA (1) | UA107689C2 (enExample) |
| WO (1) | WO2011073231A1 (enExample) |
| ZA (1) | ZA201204135B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101930561B1 (ko) | 2010-06-07 | 2018-12-18 | 사푸라스트 리써치 엘엘씨 | 재충전 가능한 고밀도 전기 화학 장치 |
| AU2012216890A1 (en) * | 2011-02-17 | 2013-09-05 | Cipla Limited | Combination of glycopyrrolate and a beta2 -agonist |
| US20140113877A1 (en) * | 2011-06-15 | 2014-04-24 | Takeda Gmbh | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds |
| WO2014016548A2 (en) * | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
| US20150322049A1 (en) * | 2012-12-13 | 2015-11-12 | Ludwig Aigner | Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease |
| JP6307524B2 (ja) | 2013-02-04 | 2018-04-04 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Ｐｄｅ４阻害薬としての、４−アミノ置換縮合ピリミジン化合物 |
| JP6505023B2 (ja) | 2013-02-19 | 2019-04-24 | ファイザー・インク | Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 |
| JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
| CN106795165B (zh) | 2014-08-06 | 2019-09-10 | 辉瑞公司 | 咪唑并哒嗪化合物 |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| WO2022006470A1 (en) | 2020-07-01 | 2022-01-06 | Vanderbilt University | Methods of treatment for a kidney disease |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3899494A (en) | 1970-05-13 | 1975-08-12 | Sandoz Ltd | Substituted 6-phenyl benzo-naphthyridines |
| DE2047465A1 (de) | 1970-09-26 | 1972-03-30 | Farbwerke Hoechst AG, vorm Meister Lucius & Bruning, 6000 Frankfurt | Neue Oxdiazole und Verfahren zu lh rer Herstellung |
| CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| JPH01213284A (ja) | 1988-02-22 | 1989-08-28 | Sankyo Co Ltd | チエノピリミジン−２，４−ジオン誘導体 |
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| DE69012458T3 (de) | 1989-05-31 | 2000-01-20 | Fisons Plc, Ipswich | Medikament und Inhalationsvorrichtung dafür. |
| GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
| IE67185B1 (en) | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| JPH05505824A (ja) | 1990-03-23 | 1993-08-26 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 所定投与量エアロゾル製剤の製造のための可溶性弗素界面活性剤の使用 |
| DE69105212T2 (de) | 1990-10-18 | 1995-03-23 | Minnesota Mining And Mfg. Co., Saint Paul, Minn. | Aerosolzubereitung, die beclometason 17,21-dipropionat enthält. |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| GB9213874D0 (en) | 1992-06-30 | 1992-08-12 | Fisons Plc | Process to novel medicament form |
| GB9306703D0 (en) | 1993-03-31 | 1993-05-26 | Fisons Plc | Inhalation device |
| IL111194A (en) | 1993-10-08 | 1998-02-08 | Fisons Plc | Process for the production of medicament formulations |
| PL189641B1 (pl) | 1996-11-11 | 2005-09-30 | Altana Pharma Ag | Benzonaftyrydyny, środki farmaceutyczne je zawierające oraz zastosowanie benzonaftyrydyn |
| WO1998050385A1 (en) | 1997-05-08 | 1998-11-12 | Merck Sharp & Dohme Limited | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS |
| WO1998055481A1 (en) | 1997-06-03 | 1998-12-10 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzonaphthyridine |
| AU749697B2 (en) | 1998-08-04 | 2002-07-04 | Jagotec Ag | Medicinal aerosol formulations |
| US6397838B1 (en) | 1998-12-23 | 2002-06-04 | Battelle Pulmonary Therapeutics, Inc. | Pulmonary aerosol delivery device and method |
| ATE336301T1 (de) | 1999-04-23 | 2006-09-15 | Ventaira Pharmaceuticals Inc | Elektrostatisches versprühen mit transfer- hoher masse |
| AU777167B2 (en) | 1999-04-23 | 2004-10-07 | Battelle Memorial Institute | Directionally controlled EHD aerosol sprayer |
| DE60024861T2 (de) | 1999-10-28 | 2006-07-06 | Trine Pharmaceuticals, Inc., Waltham | Pumpeninhibitoren zur freisetzung von medikamenten |
| WO2001094350A1 (en) | 2000-06-07 | 2001-12-13 | Almirall Prodesfarma S.A. | 6-phenylpyrrolopyrimidinedione derivatives |
| AU2001281965A1 (en) | 2000-07-14 | 2002-01-30 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Novel 6-phenylphenanthridines |
| JP5021149B2 (ja) | 2000-10-09 | 2012-09-05 | スリーエム イノベイティブ プロパティズ カンパニー | 医療用エアロゾル調合物 |
| AU2002331064B2 (en) | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| US20030216407A1 (en) | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
| GB0202254D0 (en) | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
| AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| US20050239867A1 (en) | 2004-04-23 | 2005-10-27 | Zeldis Jerome B | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension |
| EP1791847A2 (en) * | 2004-09-08 | 2007-06-06 | Altana Pharma AG | Novel 3-thia-10-aza-phenanthrene derivatives |
| DE602005027866D1 (de) | 2004-09-08 | 2011-06-16 | Nycomed Gmbh | 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4-inhibitoren |
| CA2588768A1 (en) | 2004-11-17 | 2006-05-26 | Kissei Pharmaceutical Co., Ltd. | Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both |
| JP2008532980A (ja) * | 2005-03-09 | 2008-08-21 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | アミド置換された６−フェニルフェナントリジン |
| CN101663293B (zh) | 2007-04-23 | 2013-07-31 | 塞诺菲-安万特股份有限公司 | 作为p2y12拮抗剂的喹啉-甲酰胺衍生物 |
| US20140113877A1 (en) * | 2011-06-15 | 2014-04-24 | Takeda Gmbh | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds |
-
2010
- 2010-12-14 AR ARP100104617A patent/AR079451A1/es unknown
- 2010-12-15 PT PT107905697T patent/PT2513119E/pt unknown
- 2010-12-15 SG SG2014000335A patent/SG196785A1/en unknown
- 2010-12-15 GE GEAP201012783A patent/GEP20146105B/en unknown
- 2010-12-15 DK DK10790569.7T patent/DK2513119T3/da active
- 2010-12-15 RS RSP20140499 patent/RS53544B1/sr unknown
- 2010-12-15 PH PH1/2012/501125A patent/PH12012501125A1/en unknown
- 2010-12-15 MX MX2012006696A patent/MX2012006696A/es active IP Right Grant
- 2010-12-15 EP EP10790569.7A patent/EP2513119B1/en active Active
- 2010-12-15 BR BR112012014058A patent/BR112012014058A8/pt not_active IP Right Cessation
- 2010-12-15 EA EA201200891A patent/EA023212B1/ru not_active IP Right Cessation
- 2010-12-15 PL PL10790569T patent/PL2513119T3/pl unknown
- 2010-12-15 UA UAA201208482A patent/UA107689C2/ru unknown
- 2010-12-15 CA CA2784013A patent/CA2784013A1/en not_active Abandoned
- 2010-12-15 CN CN201080057293.7A patent/CN102652136B/zh not_active Expired - Fee Related
- 2010-12-15 NZ NZ601115A patent/NZ601115A/en not_active IP Right Cessation
- 2010-12-15 KR KR1020127017957A patent/KR20120123313A/ko not_active Withdrawn
- 2010-12-15 ES ES14164018.5T patent/ES2621291T3/es active Active
- 2010-12-15 EP EP14164018.5A patent/EP2813509B1/en active Active
- 2010-12-15 SG SG2012034732A patent/SG180824A1/en unknown
- 2010-12-15 WO PCT/EP2010/069704 patent/WO2011073231A1/en not_active Ceased
- 2010-12-15 US US13/515,214 patent/US9018175B2/en not_active Expired - Fee Related
- 2010-12-15 JP JP2012543701A patent/JP5645961B2/ja not_active Expired - Fee Related
- 2010-12-15 ME MEP-2014-114A patent/ME01914B/me unknown
- 2010-12-15 ES ES10790569.7T patent/ES2505290T3/es active Active
- 2010-12-15 AU AU2010332955A patent/AU2010332955B8/en not_active Ceased
- 2010-12-15 SI SI201030746T patent/SI2513119T1/sl unknown
- 2010-12-15 HR HRP20140893AT patent/HRP20140893T1/hr unknown
- 2010-12-17 TW TW99144591A patent/TWI468411B/zh not_active IP Right Cessation
-
2012
- 2012-05-24 CO CO12085785A patent/CO6551705A2/es active IP Right Grant
- 2012-06-06 ZA ZA2012/04135A patent/ZA201204135B/en unknown
-
2014
- 2014-12-11 SM SM201400185T patent/SMT201400185B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012501125A1 (en) | 3, 4, 4a, 10b - tetrahydro -1h- thiopyrano -[4, 3-c] isoquinoline derivatives | |
| MX2008013582A (es) | Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa. | |
| JO3181B1 (ar) | مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود | |
| MX2010009416A (es) | Compuestos heterociclicos como inhibidores de cxcr2. | |
| MX2012006805A (es) | Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa. | |
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| TW200640924A (en) | VEGF-R2 inhibitors and methods | |
| SI2134691T1 (sl) | Derivati kvinolina kot PARP in TANK inhibitorji | |
| PH12014500373A1 (en) | Amino quinazolines as kinase inhibitors | |
| EP2566477A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS | |
| MX2012008141A (es) | Compuestos y metodos. | |
| MX2011007998A (es) | Nuevos herbicidas. | |
| MY161132A (en) | Novel herbicides | |
| SG195319A1 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| PH12015500345A1 (en) | Amino-quinolines as kinase inhibitors | |
| MX2011007932A (es) | Herbicidas nuevos. | |
| MX2009013515A (es) | Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica. | |
| TN2009000267A1 (en) | 6-benzyl-2,3,4,7-tetrahydro-indolo [2, 3-c] quinoline compounds useful as pde5 inhibitors | |
| TN2011000355A1 (en) | Novel microbiocides | |
| MX2011007165A (es) | Derivados de piridazinona. | |
| MX2010009276A (es) | Pirrolopirimidincarboxamidas. | |
| MY154498A (en) | Pyrazolone derivatives as pde4 inhibitors | |
| UA85505C2 (en) | Kinase inhibitors | |
| TN2012000034A1 (en) | Methylpyrrolopyrimidinecarboxamides | |
| AU2013314244A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: ROTTAPHARM BIOTECH S.R.L. |
|
| FG | Grant or registration |